← Leaderboards
Karen P Alexander
Duke University
$27,753,285
Attributed
$38,777,657
Total exposure
8
Grants
6
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $21.6M · FY2012–25$25M$18.8M$12.5M$6.3M$0
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$122,767,209 · 9
By mechanism
U19$102,013,933 · 7
U01$16,866,873 · 1
UG3$3,886,403 · 1
Top collaborators
- Sean M O'Brien8 shared
- Walter T Ambrosius6 shared
- Adrian Hernandez6 shared
- Jeff Douglas Williamson6 shared
- Pamela Susan Douglas1 shared
- Neha Jadeja Pagidipati1 shared
Most similar at Duke University
Same institution · by research overlap
- Adrian Hernandez$126,943,012
- Sean M O'Brien$12,883,796
- Miles Berger$6,972,812
- Daniel K Benjamin$109,874,279
- Daniel B Mark$29,174,449
Others in their field
Top investigators on “Alzheimer&Apos”
- Jose A Luchsinger · Columbia University Health Sciences$56,595,040
- Eric M Reiman · Banner Health$48,982,487
- Yadong Huang · J. David Gladstone Institutes$40,311,515
- Lindsay A. Farrer · Boston University Medical Campus$34,189,802
- David M Holtzman · Washington University$28,985,806
- Michael W Weiner · Northern California Institute Res &Educ$28,197,224
Research focus
Alzheimer&AposEventReportingLeadershipClinical TrialsInternationalPharmaceutical PreparationsPreventUnited States National Institutes Of HealthSiteParticipantEvaluationCardiovascular SystemLipidsMonitorDementiaCoronary Heart DiseaseHeart FailureDisabilityRecruitCessation Of LifePhysical FunctionHospitalizationMedical Schools
Grant awards (27)
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$10,487,354
U19 · FY2025 · AG · contact PI
1/2 PREEMPT: Prospective RandomizEd Evaluation and Management of Premature aTherosclerosis$3,886,403
UG3 · FY2025 · HL
PREVENTABLE Trial Implementation Phase$2,106,576
U19 · FY2025 · AG · contact PI
PREVENTABLE Administrative and Trial Management$654,758
U19 · FY2025 · AG · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$13,319,036
U19 · FY2024 · AG · contact PI
PREVENTABLE Trial Implementation Phase$2,393,279
U19 · FY2024 · AG · contact PI
PREVENTABLE Administrative and Trial Management$746,412
U19 · FY2024 · AG · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$15,644,347
U19 · FY2023 · AG · contact PI
PREVENTABLE Trial Implementation Phase$2,238,866
U19 · FY2023 · AG · contact PI
PREVENTABLE Administrative and Trial Management$737,184
U19 · FY2023 · AG · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$18,482,472
U19 · FY2022 · AG · contact PI
PREVENTABLE Trial Implementation Phase$2,372,685
U19 · FY2022 · AG · contact PI
PREVENTABLE Administrative and Trial Management$733,289
U19 · FY2022 · AG · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$15,392,504
U19 · FY2020 · AG · contact PI
PREVENTABLE Vanguard Phase$3,322,350
U19 · FY2020 · AG · contact PI
PREVENTABLE Administrative and Trial Management$1,019,217
U19 · FY2020 · AG · contact PI
PRagmatic EValuation of evENTs And Benefits of Lipid-lowering in oldEr Adults (PREVENTABLE)$10,663,839
U19 · FY2019 · AG · contact PI
The ISCHEMIA Trial - SDCC$1,975,010
U01 · FY2019 · HL
PREVENTABLE Protocol Refinement and Study Start-up Phase$981,241
U19 · FY2019 · AG · contact PI
PREVENTABLE Administrative and Trial Management$718,524
U19 · FY2019 · AG · contact PI
The ISCHEMIA Trial - SDCC$2,058,580
U01 · FY2018 · HL
The ISCHEMIA Trial - SDCC$1,979,422
U01 · FY2018 · HL
The ISCHEMIA Trial - SDCC$2,200,028
U01 · FY2017 · HL
The ISCHEMIA Trial - SDCC$2,134,208
U01 · FY2015 · HL
The ISCHEMIA Trial - SDCC$2,085,736
U01 · FY2014 · HL
The ISCHEMIA Trial - SDCC$500,000
U01 · FY2013 · HL
The ISCHEMIA Trial - SDCC$3,933,889
U01 · FY2012 · HL